Outstanding Results from Truscreen Indian Screening Trial

NZX Announcement

14 January 2020

Outstanding Results from TruScreen Indian Screening Trial

Highlights

• TruScreen’s real-time cervical cancer screening device has demonstrated
improved sensitivity and specificity targeting pre-cancerous and cancerous
cervical cells compared to a Pap test in a trial in India
• India is a significant potential market for TruScreen
• The national All India Institute of Medical Sciences (AIIMS) conducted the trial
involving 645 women at a tertiary referral centre in New Delhi and at a
comprehensive rural health services centre at Ballabgarh, Haryana


Auckland - Real-time cervical cancer screening technology company TruScreen (NZX:
TRU) or (“the Company”) says results from its first cervical cancer screening trial in India
confirm that the TruScreen device is an effective, viable and non-invasive method of
detecting cervical intra-epithelial neoplasia (CIN).

The trial, conducted by the All India Institute of Medical Sciences (AIIMS) in New Delhi
and the town of Ballabgarh over the period January 2018 to February 2019, screened
645 women for cervical cancer.

All women in the trial underwent screening for CIN, using TruScreen’s opto-electrical
device and a Pap test. The sensitivity of the TruScreen device to detect CIN was 81.82%
compared to 72.73% by the Pap test. The specificity of the TruScreen device was 82.87%
compared to 79.81% by the Pap test.

Sensitivity and specificity are measures of a screening test’s ability to correctly identify
disease. A high sensitivity results in fewer false negatives, and a high specificity results
in fewer false positives in the screening process.

“This is an important outcome for TruScreen in India, which is a significant potential
market for the TruScreen real-time cervical cancer screening device,” says TruScreen
Chairman Tony Ho. “TruScreen has demonstrated again to be a cost-effective solution
for detecting CIN and improving the lives of women in low- and middle-income countries.”

The TruScreen device’s ability to provide test results in real time without the need to
access pathology infrastructure is its distinguishing feature. In comparison, collected
tissue samples from a Pap test must be processed at a pathology laboratory, where the
typical turnaround time is two to six weeks. Faster test results enable patients to access
follow-up reviews for medical treatment more quickly.

Results of the TruScreen trial have been submitted to the Journal of the Indian Medical
Association for publication.

TruScreen thanks the AIIMS team (Principal Investigator: Prof. J. B. Sharma, Professor,
Obstetrics & Gynaecology; and Co-Investigators: Prof. Alka Kriplani, Professor and Head,
Department of Obstetrics & Gynaecology AIIMS, New Delhi; Prof. Sandeep Mathur,
Professor, Department of Pathology, AIIMS, New Delhi) and our Indian distributors
(Khandelwal laboratories) for their collaboration with the TruScreen team for this study.

- ENDS -


For more information, visit www.truscreen.com or contact:

TruScreen
Tony Ho
Chairman
tonyho@truscreen.com

TruScreen
Guy Robertson
CFO
guyrobertson@truscreen.com
Investors
Investor Relations
Phone: +61 2 9237 2801
TruScreen@we-
worldwide.com


About TruScreen:

TruScreen is a Cervical Cancer Screening Device
which offers the latest technology in cervical
screening, providing real-time, accurate detection
of pre-cancerous and cancerous cervical cells to
help improve the health and well-being of women
around the world. TruScreen’s real-time cervical
cancer technology utilises a digital wand which is
placed on the surface of the cervix to measure
electrical and optical signals from the surrounding
tissues. A sophisticated proprietary algorithm
framework is utilised to detect pre-cancerous change,
or cervical intra-epithelial neoplasia (CIN), by optical
and electrical measurement of cervical tissue.

TruScreen offers an alternative approach to cervical screening, resolving many of the
ongoing issues with Pap tests, including failed samples, poor patient follow-up, patient
discomfort and the need for supporting laboratory infrastructures. As such, TruScreen’s
target market is low- and middle-income countries where no large-scale cervical cancer
screening programs and infrastructure are in place, such as China, Mexico, Africa,
Russia and India. TruScreen’s cervical cancer screening device is CE-marked and
certified for use throughout Europe and CFDA-approved for sale in China. The global
market potential for TruScreen is significant.

For more information, visit our website at www.truscreen.com

Watch our video on TruScreen: http://truscreen.com/truscreen-the-company/truscreen-
ultra-video/